Stocks
Cara Therapeutics (CARA) EBITDA US GAAP (year values) |
|||||||||
| 2020 | 2021 | 2022 | 2023 | 2023 | LTM ? | CAGR 5 years ? | |||
| EBITDA, bln rub | ? | 5.59 | -88.2 | -83.8 | -121.5 | -117.7 | -88.8 | ||
| Changes by years, y/y, % | -105% | -1 677% | -5% | +45% | -3% | +8.7% | |||
Cara Therapeutics. EBITDA US GAAP, bln rub
Cara Therapeutics. EBITDA US GAAP, changes, %
Cara Therapeutics. EBITDA US GAAP, sum by quarters, bln rub
Cara Therapeutics (CARA) EBITDA US GAAP (quarter values) |
||||||||
| 2023Q4 | 2023Q4 | 2024Q1 | 2024Q2 | 2024Q3 | LTM ? | |||
| EBITDA, bln rub | ? | -32.6 | -31.7 | -28.7 | -18.0 | -10.4 | -88.8 | |
| Changes by years, y/y, % | +4% | +1% | +4% | -42% | -64% | |||
| Changes by quarters, q/q, % | +13% | -3% | -9% | -37% | -42% | |||
